| 000 | 01474 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513042927.0 | ||
| 264 | 0 | _c19950630 | |
| 008 | 199506s 0 0 eng d | ||
| 022 | _a0009-9236 | ||
| 024 | 7 |
_a10.1016/0009-9236(95)90035-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDingemanse, J | |
| 245 | 0 | 0 |
_aIntegrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cMay 1995 |
||
| 300 |
_a508-17 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBenzophenones _xadverse effects |
| 650 | 0 | 4 | _aCatechol O-Methyltransferase Inhibitors |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntestinal Absorption |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNitrophenols |
| 650 | 0 | 4 | _aTolcapone |
| 700 | 1 | _aJorga, K M | |
| 700 | 1 | _aSchmitt, M | |
| 700 | 1 | _aGieschke, R | |
| 700 | 1 | _aFotteler, B | |
| 700 | 1 | _aZürcher, G | |
| 700 | 1 | _aDa Prada, M | |
| 700 | 1 | _avan Brummelen, P | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 57 _gno. 5 _gp. 508-17 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0009-9236(95)90035-7 _zAvailable from publisher's website |
| 999 |
_c7767441 _d7767441 |
||